Clinical trial
A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination With Taxotere® (Docetaxel) in the Treatment of Subjects With Solid Tumors
NCT00888108 is registered in ClinicalTrials.gov with Abbott as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination With Taxotere® (Docetaxel) in the Treatment of Subjects With Solid Tumors
- Lead sponsor
- Abbott
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 31, 2009
- Completion date
- March 31, 2012
- Enrollment
- 41 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
solid tumor